About
1910 Genetics is the only biotech company advancing small and large molecule drug discovery with an automated, multimodal AI platform. We integrate AI with three proprietary data streams – computational data, wet lab gold standard biological data and wet lab proxy biological data – to deliver novel drug candidates to leading pharma and tech partners, and advance our own pipeline for neurological, autoimmune diseases, and cancer. 1910 was launched in 2021 with a combined seed and Series A funding of $26.1M backed by M12-Microsoft’s Venture Fund, Playground Global, OpenAI’s Sam Altman, and other leading investors. We have since established our HQ and lab facilities in Boston’s Seaport District and continue to hire a world-class team. To learn more visit 1910genetics.com.
BostonMachine LearningArtificial IntelligenceBiotechnology